A randomized, open-label phase II studyevaluating the efficacy and safety of FOLFOX-4plus cetuximab versus UFOX plus cetuximab asfirst-line therapy in subjects with metastaticcolorectal cancer
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2519204
下载链接
链接失效反馈官方服务：
资源简介：
Primary objectives: The primary objective of this study is to compare the PFS in subjects receiving cetuximab plus either UFOX or FOLFOX-4 as initial treatment for metastatic colorectal cancer.
Primary endpoints: The primary variable is progression-free survival.
创建时间：
2006-11-15
